Premium
FDA authorizes marketing of diagnostic aid for Autism Spectrum Disorder
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30601
Subject(s) - autism spectrum disorder , food and drug administration , psychiatry , medicine , health care , autism , family medicine , psychology , business , medical education , marketing , medical emergency , economic growth , economics
In June, the U.S. Food and Drug Administration authorized marketing of a device to help diagnose autism spectrum disorder (ASD). The Cognoa ASD Diagnosis Aid is a machine learning‐based software intended to help health care providers diagnose ASD in children 18 months through 5 years of age who exhibit potential symptoms of the disorder.